CA3142196A1 - Crystalline polymorphs of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative - Google Patents

Crystalline polymorphs of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative Download PDF

Info

Publication number
CA3142196A1
CA3142196A1 CA3142196A CA3142196A CA3142196A1 CA 3142196 A1 CA3142196 A1 CA 3142196A1 CA 3142196 A CA3142196 A CA 3142196A CA 3142196 A CA3142196 A CA 3142196A CA 3142196 A1 CA3142196 A1 CA 3142196A1
Authority
CA
Canada
Prior art keywords
crystalline polymorph
provides
cancer
xrpd pattern
pyrazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3142196A
Other languages
English (en)
French (fr)
Inventor
Alan Cooper
Zheqiong WU
Shanming KUANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bantam Pharmaceutical LLC
Original Assignee
Bantam Pharmaceutical LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bantam Pharmaceutical LLC filed Critical Bantam Pharmaceutical LLC
Publication of CA3142196A1 publication Critical patent/CA3142196A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3142196A 2019-05-31 2020-05-29 Crystalline polymorphs of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative Pending CA3142196A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962855671P 2019-05-31 2019-05-31
US62/855,671 2019-05-31
PCT/US2020/035343 WO2020243584A1 (en) 2019-05-31 2020-05-29 Crystalline polymorphs of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative

Publications (1)

Publication Number Publication Date
CA3142196A1 true CA3142196A1 (en) 2020-12-03

Family

ID=71787116

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3142196A Pending CA3142196A1 (en) 2019-05-31 2020-05-29 Crystalline polymorphs of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative

Country Status (7)

Country Link
US (1) US12378234B2 (https=)
EP (1) EP3976606A1 (https=)
JP (2) JP2022534429A (https=)
CN (1) CN114901655A (https=)
AU (2) AU2020283129A1 (https=)
CA (1) CA3142196A1 (https=)
WO (1) WO2020243584A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3081983A1 (en) * 2016-11-30 2018-06-07 Bantam Pharmaceutical, Llc Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1248869A2 (en) * 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
US12150934B2 (en) 2016-11-30 2024-11-26 Bantam Pharmaceutical, Llc Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases
CA3081983A1 (en) * 2016-11-30 2018-06-07 Bantam Pharmaceutical, Llc Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases

Also Published As

Publication number Publication date
AU2026201586A1 (en) 2026-03-19
JP2022534429A (ja) 2022-07-29
CN114901655A (zh) 2022-08-12
US20220162204A1 (en) 2022-05-26
AU2020283129A1 (en) 2022-02-03
WO2020243584A1 (en) 2020-12-03
US12378234B2 (en) 2025-08-05
EP3976606A1 (en) 2022-04-06
JP2025160244A (ja) 2025-10-22

Similar Documents

Publication Publication Date Title
TW202115065A (zh) Kras突變蛋白抑制劑
JP6402179B2 (ja) 新規な、ＮＩＫ阻害剤としての１−（４−ピリミジニル）−１Ｈ−ピロロ［３，２−ｃ］ピリジン誘導体
JP7853221B2 (ja) ４－アミノ－５－（６－（４－メチルピペラジン－１－イル）－１ｈ－ベンゾ［ｄ］イミダゾール－２－イル）チエノ［２，３－ｂ］ピリジン－６（７ｈ）－オンの塩及び結晶形
JP2020079302A (ja) カンナビノイド受容体モジュレーター
KR101738866B1 (ko) 안드로겐 수용체 길항제, 항암제로서 사이클릭 n,n'-다이아릴티오우레아 및 n,n'-다이아릴우레아, 이의 제조방법 및 이의 용도
TW201236684A (en) Pharmaceutically acceptable salts of (E)-N-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolyl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide, preparation process and pharmaceutical use there of
AU2026201586A1 (en) Crystalline polymorphs of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative
EP2776407A1 (en) Modulators of the g protein-coupled mas receptor and the treatment of disorders related thereto
ES2949616T3 (es) Compuestos de aminotiazol como inhibidores de proteína cinasa
CA2960574A1 (en) Pyrazolopyrimidine derivatives as nik inhibitors
AU2017262155B2 (en) Certain protein kinase inhibitors
US20070244110A1 (en) Treatment of prostate cancer, melanoma or hepatic cancer
JP2019512011A (ja) 置換のアミノ６員窒素含有複素環式化合物およびその製造と使用
KR20150023880A (ko) 안드로겐 수용체 길항제로서의 ｎ-[4-(퀴놀린-4-일옥시)사이클로헥실(메틸)](헤테로)아릴카복사미드, 그의 제조, 및 의약품으로서의 그의 용도
US20210053951A1 (en) Salt Forms Of 4-Cyano-N-(4,4-Dimethylcyclohex-1-EN-1-YL)-6-(2,2,6,6-Tetramethyltetrahydro-2H-Pyran-4-YL)Pyridin-3-YL)-1H-Imidazole-2-Carboximide
CN104045632B (zh) 抗肿瘤药物苯并二氢吡喃（噻喃）酰胺类化合物及其药学上可接受的盐及制备方法和应用
CA3023460C (en) Cdk4/6 inhibitors for the treatment of hyper-proliferative diseases
BR112019026577B1 (pt) Compostos aminotiazol, composição farmacêutica e uso como inibidores de proteína quinase e no tratamento de câncer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240528

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250425

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250425

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250619

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251020

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251215

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251215

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251215

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260423

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260423